Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1866MR)

This product GTTS-WQ1866MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1866MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10708MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ4400MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ6399MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ12218MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ15206MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ7030MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ4081MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ5973MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CLLB8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW